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Background
Expansion of antigen-specific T cells, from peripheral
blood specific for tumor-associated antigens (TAAs) is a
prerequisite for the advanced cellular therapy. Such anti-
gen-specific T cells should express a Th1-functional
phenotype and are able to enter tumor-tissue. We iden-
tified a cytokine cocktail, comprised of IL-2, IL-15 and
IL-21 that drives antigen-specific T cells from peripheral
blood mononuclear cells to tumor-associated antigens.
Materials and methods
20 blood samples (3 from health donors, 11 from glioma
patients and 6 from pancreatic cancer patients) were col-
lected, T cells were expanded using the cytokine cocktail
IL-2/IL-15/IL-21 and TAAs, e.g. NY-ESO-1 or infectious
antigens, e.g. CMV pp65 within 18-21 days. Intracellular
Cytokine Staining (ICS) was used to detect antigen-specific
immune responses by combining CD3, CD4 and CD8 mar-
kers with IL-2, TNF-a, IFN-g production. Chemokine mar-
kers like CCR4, CCR6 or CXCR3 were used for
phenotyping distinguishing Th1 and Th2 subtypes in CD4
+ T cells, as well as in CD3+, CD4-CD8- (double-negative)
T cell subsets. T cell memory phenotypes were defined by
CCR7 and CD45RA staining. Tetramer (NY-ESO-1 or
CMV specific) staining were used to show expansion of
antigen specific T cells using a panel of mutant MHC class
I tetramer molecules that allow to gauge for high, inter-
mediate and low-affinity T cell populations imposed by
interference of the MHC class I heavy chain with the
CD8a binding site.
Results
T cells from peripheral blood could be expanded (up
to 10e10 cells) using IL-2, IL-15 and IL-21 and TAA-
specific CD8, CD4 and CD3+, CD4-CD8-T cells could
reliably be expanded defined by intracellular cytokine
staining. In general, Th1 cells (CCR4-CXCR3+CCR6-)
could be readily expanded along with (i.e. from 22.2% to
92.1%) along with increased expression of CXCR3 in
both CD8+ and CD4+ T cells that enables increased
access to tumor tissue. MHC class I-reactive T cells,
directed against single T cell epitopes could be observed
in up to 10% of CD8+, NY-ESO-1 specific T cells with a
strong expansion of ‘high affinity’ T cells defined by i)
mutant tetramers that interfere with CD8 engagement
and ii) TAA-reactive T cells in the CD3+, CD4-CD8-
double negative T cell subset.
Conclusions
T cells from peripheral blood samples can be reliably and
successfully expanded in IL-2, IL-15 and IL-21, they show
high affinity TCR – MHC class I/peptide engagement, a
Th1-cytokine production pattern and increased CXCR3
expressing allowing T cell access into tissues. A Phase I
clinical trial to target TAAs in patients with glioblastoma
or pancreatic cancer will soon start at Karolinska using
IL-2/IL-15/IL-21 and TAA-expanded T cells.
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